GATA1 mutations in Down Syndrome: Implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia

Citations Over TimeTop 10% of 2004 papers

Abstract

Although physicians have known for many decades that children with Down syndrome are predisposed to developing transient myeloproliferative disorder (TMD) and acute megakaryoblastic leukemia (AMKL), many questions regarding these disorders remain unresolved. First, what is the relationship between TMD and AMKL? Second, what specific genetic alterations contribute to the leukemic process? Finally, what factors lead to the increased predisposition to these myeloid disorders? In this review I will summarize important new insights into the biology of TMD and AMKL gained from the recent discovery that GATA1, a gene that encodes an essential hematopoietic transcription factor, is mutated in the leukemic blasts from nearly all patients with these malignancies. In addition, I will discuss whether assaying for the presence of a GATA1 mutation can aid in the diagnosis of these and related megakaryoblastic leukemias. Future research aimed at defining the activity of mutant GATA-1 protein and identifying interacting factors encoded by chromosome 21 will likely lead to an even greater understanding of this intriguing leukemia.

Related Papers

• → GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome(2003)324 cited
• → Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi‐step model of myeloid leukaemogenesis(2009)126 cited
• → Acute megakaryoblastic leukemia in Down syndrome(2007)28 cited
• → Transient Myeloproliferative Disorder and GATA1 Mutation in Neonates With and Without Down Syndrome(2011)19 cited
• → Evolution of myeloid leukemia in children with Down syndrome(2016)16 cited